title: Critical appraisal of the guidelines for the management of ankylosing spondylitis:  disease-modifying antirheumatic drugs.
abstract: Surprisingly, little data are available for the use of disease-modifying antirheumatic drugs in ankylosing spondylitis. Sulfasalazine has been the best studied. Efficacy data for individual agents (including pamidronate) and combinations of agents are detailed in this review. Intriguingly, these agents continue to be used with some frequency, even in the absence of efficacy data. To answer these questions, additional systematic studies of these agents in ankylosing spondylitis are needed and will likely need to be done by interested collaborative groups such as SPARTAN.
authors.affiliation: Hospital Italiano de Buenes Aires, Argentina.
authors.forename: Enrique R
authors.initials: ER
authors.lastname: Soriano
authors.forename: Daniel O
authors.initials: DO
authors.lastname: Clegg
authors.forename: Jeffrey R
authors.initials: JR
authors.lastname: Lisse
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D017410:Practice Guidelines as Topic; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D017211:Treatment Failure
chemical_list: D018501:Antirheumatic Agents